Skip to main content

Year: 2019

InnerScope Hearing Technologies (OTCQB: INND) Reports Strong Q3 2019 Revenue Growth of over Q3 2018 & Q3 Business Progress

419% Revenue Growth for Q3 2019396% Revenue Growth Year-over-Year22% Revenue Growth over Q2 2019    ROSEVILLE, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — InnerScope Hearing Technologies Inc. (OTCQB: INND) (“InnerScope”) a manufacturer and Direct-to-Consumer (“DTC”) distributor/retailer of FDA-Registered Hearing Aids, Personal Sound Amplifiers Products, (“Hearing Products”) Hearing Related Treatment Therapies, Doctor-Formulated Dietary Hearing Supplements and proprietary CBD Oil (“Hearing Health Products”) (collectively “Hearing Product Portfolio”), today announced its unaudited third quarter revenue results ended September 30, 2019 (“Q3 2019”) of $250,781, a revenue growth of 419% over the third quarter ended September 30, 2018 (“Q2...

Continue reading

Atos partners with Zapata to deliver complete quantum computing solution to the enterprise

Paris, France and Irving, Texas, November 18, 2019 – Atos, a global leader in digital transformation, and US-based Zapata Computing Inc., a leading enterprise software company for quantum applications, today announced a global partnership to deliver an end-to-end quantum computing solution that combines Zapata’s software platform Orquestra™ (Orquestra) with the Atos Quantum Learning Machine (QLM) to address vertical markets.The joint solution allows organizations to engage the world’s most difficult computational problems within oil and gas, aviation, finance and pharmaceutical industries with a unique approach ready to deploy and scale to real-world challenges. In addition, Atos and Zapata will also come together to provide comprehensive consulting services to help customers become quickly up-to-speed on the capabilities of quantum computing...

Continue reading

Atos s’associe avec Zapata fournir une solution d’informatique quantique aux entreprises

Paris, France – Irving, Texas, Etats-Unis – Le 18 novembre 2019 – Atos, leader international de la transformation digitale, et l’entreprise Zapata Computing Inc., un acteur de renommée mondiale dans le domaine des algorithmes quantiques, basé aux Etats-Unis, annoncent aujourd’hui un partenariat mondial pour fournir une solution d’informatique quantique de bout-en-bout qui combine la plateforme logicielle de Zapata, Orquestra™ (Orchestra), et l’Atos Quantum Learning Machine (Atos QLM) pour s’adresser aux différents marchés verticaux.La solution conjointe permet aux organisations de s’attaquer aux problèmes de calcul les plus complexes dans les secteurs du pétrole et du gaz, de l’aviation, de la finance et de l’industrie pharmaceutique avec une approche unique, prête à être déployée et adaptable...

Continue reading

Michelin: Disclosure of trading in own shares – Period from 8 to 14 November 2019

SECURITIES REPURCHASING PROGRAMME(Decided by the annual shareholders’ meeting of 17 May 2019)Disclosure of trading in own sharesPeriod from 8 to 14 November 2019Issuer : COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELINLEI : 549300SOSI58J6VIW052Types of securities: ordinary shares (ISIN : FR 0000121261)Full details of the programme disclosed on 30 August 2019Purchases effected during the period:(*) Shares purchased through a derivative instrument are included. Are excluded transactions carried out in connection with the execution of a contract to increase share market liquidity.AttachmentModèle EN déclaration hèbdo 18.11.19

Continue reading

Michelin : Déclaration des transactions sur actions propres – Période du 8 au 14 novembre 2019

PROGRAMME DE RACHAT DE TITRES(Programme adopté par l’assemblée générale mixte des actionnaires le 17 mai 2019)Déclaration des transactions sur actions propresPériode du 8 au 14 novembre 2019Emetteur : COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELINLEI : 549300SOSI58J6VIW052Catégories de titres : actions ordinaires (ISIN : FR 0000121261)Descriptif du programme publié le 30 août 2019Achats réalisés au cours de la période :(*) Y compris les titres acquis par l’intermédiaire d’un produit dérivé, mais compte non tenu des opérations réalisées dans le cadre de l’exécution d’un contrat de liquidité.Pièce jointeModèle FR déclaration hèbdo 18.11.19

Continue reading

Deflamo AB: Extra bolagsstämma (tillika andra kontrollstämma) i Deflamo AB

Pressmeddelande Deflamo AB Extra bolagsstämma (tillika andra kontrollstämma) i Deflamo ABFör ytterligare information, vänligen kontaktaJan Blomquist, OrdförandeTel: +46 (0)70-486 17 71E-mail: jan@blomquist.beLäs mer om Deflamo AB på www.deflamo.comBolaget är listat på Nasdaq First North. Mangold Fondkommission AB, telefonnummer +46 8 5030 1550, ca@mangold.se, är bolagets Certified Adviser.BilagaStämmokommuniké 18 november 2019

Continue reading

Quinsam Reports Q3/2019 Results

TORONTO, Nov. 18, 2019 (GLOBE NEWSWIRE) — Quinsam Capital Corporation (CSE:QCA) (“Quinsam” or the “Company”) is pleased to announce its Q3/2019 results, with net loss of $5.2 million ($0.05 per share basic, $0.04 fully diluted) versus net income of $2.1 million ($0.02 per share basic, $0.01 fully diluted) in Q3/2018. Investors can access the company’s full financial statements on sedar.com.“At September 30, 2019, we had net assets of approximately $0.34 per share equivalent outstanding,” said Roger Dent, CEO of Quinsam. “Even though our NAV reflects the Q3 market carnage in the cannabis space, our trading price remains at an extremely large discount to our underlying asset value.”Quinsam notes that the cannabis sector generally had very negative performance in Q3/2019. For example, the Horizon Marijuana Life Sciences Index ETF NAV...

Continue reading

Lumina Gold Secures Key Land For Project Development

Highlights:400.5 hectares of land secured for facility siting and other uses79.5 hectares of land secured to the north of Gran Bestia where the deposit remains openLumina currently controls all of the surface area over the Cangrejos and Gran Bestia deposits1,512.3 hectares are now controlled through direct land ownership and easementsVANCOUVER, British Columbia, Nov. 18, 2019 (GLOBE NEWSWIRE) — Lumina Gold Corp. (TSXV: LUM) (OTCQX: LMGDF) (the “Company” or “Lumina”) is pleased to announce the signing of two agreements with private individuals to acquire approximately 480.0 hectares of land and surface rights. 400.5 hectares of the secured land are located to the west of the known Cangrejos and Gran Bestia mineralization and will provide a large area that could accommodate facility siting and could also be used for buffer and environmental...

Continue reading

Stein Mart Introduces Fine Jewelry

JACKSONVILLE, Fla., Nov. 18, 2019 (GLOBE NEWSWIRE) — Stein Mart (NASDAQ: SMRT) today announced it has launched a fine jewelry department in 51 stores and online, as well as a key item fine jewelry program in all stores. This news follows the company’s announcement of its new Kids department.The fine jewelry collection, called “Stein Mart Jewel Box”, features beautiful diamonds, pearls, 14K gold, gemstones and designer branded jewelry with prices ranging from $200 to $5000. At 40-60% off competitors’ prices, Stein Mart’s fine jewelry is sure to satisfy any shopper’s desire for luxury at an exceptional value. While currently available in select stores and online, the company plans to roll out the full assortment to more doors in 2020.Just in time for holiday gift giving, Stein Mart has also introduced a key item fine jewelry program...

Continue reading

TG Therapeutics to Present at the Jefferies London Healthcare Conference

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference, being held at the Waldorf Hilton on Aldwych, in London, UK. The presentation is scheduled to take place on Wednesday, November 20, 2019 at 11:20 AM GMT.A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.